Camardo Daniel A. 4

What Happened

• Daniel A. Camardo, a director of Cue Biopharma, received a grant of 21,800 restricted stock units (RSUs) reported on Form 4. The filing shows an acquisition price of $0 and a reported total value of $0 (typical for RSU grants where no cash is paid at grant).
• Per the filing footnote, the RSUs vest in three equal installments: one‑third on each of July 9, 2027; July 9, 2028; and July 9, 2029, subject to continued service.

Key Details

• Transaction date: 2026-07-09; Form 4 filed: 2026-07-10 (appears timely).
• Reported shares granted: 21,800 RSUs; reported acquisition price: $0; reported total value: $0.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: Vesting schedule — one-third vests on each of 7/9/2027, 7/9/2028, 7/9/2029, subject to continued service.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context

• RSU grants are a form of compensation, not an immediate purchase of shares. They convert to actual shares only as they vest, and the eventual value depends on Cue Biopharma’s share price at vesting.
• Such awards align insiders’ interests with long‑term shareholder value but do not necessarily indicate a near‑term bullish or bearish signal since no cash was exchanged and no immediate sale occurred.